Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

11.47 -0.44 (-3.65%)

Delayed Quote Updated: 2:05 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding ↗

July 15, 2021

It's a good time to be a gene-editing company.

Via The Motley Fool

Russell 2000 Traders Place Bearish Bets Via IWM ETF ↗

July 13, 2021

The iShares Russell 2000 ETF (NYSE: IWM) has been trading sideways for the better part of the last six months between $211 and its all-time high of $234.53 from March 15. IWM...

Via Benzinga

WHO Issues Framework For Governance For Gene Editing Technologies ↗

July 12, 2021

A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or...

Via Benzinga

A Comprehensive Guide To Genomic ETFs ↗

July 11, 2021

Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon...

Via Talk Markets

Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results ↗

July 11, 2021

There are still some key unanswered questions for the biotech's promising gene-editing therapy.

Via The Motley Fool

Analyst Ratings For Intellia Therapeutics ↗

June 29, 2021

Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA

Via Benzinga

US Stocks Technical Analysis: AVAV, ESLT, ICE, HDFC, NTLA & NVDA ↗

July 10, 2021

Elliott Wave Technical Analysis for AeroVironment, Elbit Systems, Intercontinental Exchange, HDFC Bank Limited, Intellia Therapeutics, and Nvidia.

Via Talk Markets

Is It Too Late to Buy Intellia Therapeutics? ↗

July 10, 2021

After skyrocketing 68% last week, will this stock keep running higher?

Via The Motley Fool

Here's Why Regeneron Gained 11% Last Month ↗

July 07, 2021

The biopharma outfit dropped news that may mean more for the medicine industry than anybody fully understands.

Via The Motley Fool

2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won't ↗

July 04, 2021

After the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock skyrocketed.

Via The Motley Fool

Stock Market Rally: S&P 500, Nasdaq Hit Highs; Facebook, Tesla, Nio, Intellia, Didi IPO, OPEC+ In Focus ↗

July 02, 2021

The S&P 500 and Nasdaq hit record highs last week. Facebook hit a $1 trillion market cap. Tesla deliveries jumped.

Via Investor's Business Daily

Topics Initial Public Offering Stocks

Here's What Drove Gene Editing Stocks Higher This Week ↗

July 02, 2021

The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.

Via The Motley Fool

The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts ↗

July 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE...

Via Benzinga

5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now ↗

July 01, 2021

Despite a threat from Intellia on the horizon, Alnylam's still in a position to deliver big gains for patient investors.

Via The Motley Fool

Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders ↗

July 01, 2021

Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven...

Via Benzinga

72 Biggest Movers From Yesterday ↗

July 01, 2021

Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN...

Via Benzinga

Topics Initial Public Offering

'Halftime Report' Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond ↗

June 30, 2021

Amy Raskin said on CNBC's "Fast Money Halftime Report" that she would hold Crispr Therapeutics AG (NASDAQ: CRSP). She doesn't own the stock, but she owns...

Via Benzinga

Why Intellia Therapeutics Was a Winner on Wednesday ↗

June 30, 2021

The company is about to fatten its coffers significantly.

Via The Motley Fool

In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC ↗

June 30, 2021

Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body. What Happened: On Monday,...

Via Benzinga

Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar ↗

June 30, 2021

Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia.

Via InvestorPlace

Why Gene Editing Stocks Are Trading Higher Again Today ↗

June 30, 2021

Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

June 30, 2021

Gainers Dare Bioscience (NASDAQ:DARE) stock moved upwards by 26.82% to $2.08 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume...

Via Benzinga

51 Stocks Moving In Wednesday's Mid-Day Session ↗

June 30, 2021

Gainers Cuentas Inc. (NASDAQ: CUEN) shares jumped 176.6% to $7.69. The stock spiked following a press release saying "WaveMax to Implement the World's First Shared Wifi6...

Via Benzinga

Unusual Options Activity Insight: Intellia Therapeutics ↗

June 30, 2021

Shares of Intellia Therapeutics (NASDAQ:NTLA) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved up to $183.36. Sentiment...

Via Benzinga

Stocks That Hit 52-Week Highs On Wednesday ↗

June 30, 2021

This morning 132 companies reached new 52-week highs. Noteworthy Mentions: The largest company by market cap to break to a new 52-week high was NVIDIA (NASDAQ:NVDA...

Via Benzinga

The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs ↗

June 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ...

Via Benzinga

Intellia Therapeutics Stock Moves Higher After Capital Raise Of $600M Issued At $145/Share ↗

June 30, 2021

Intellia Therapeutics Inc (NASDAQ: NTLA) has priced a previously announced public offering at $145 per share, representing a discount of 4.4% from the last close...

Via Benzinga

Can Intellia Therapeutics Turn Exciting Trial Results into Profits? ↗

June 30, 2021

New proof-of-concept results are a big deal for the medical community, but what about for your portfolio?

Via The Motley Fool

58 Biggest Movers From Yesterday ↗

June 30, 2021

Gainers BSQUARE Corporation (NASDAQ: BSQR) shares jumped 206.9% to close at $8.04 on Tuesday on abnormally-high volume possibly amid increased attention from retail investors....

Via Benzinga

Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated ↗

June 29, 2021

Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust ...

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

All News about Intellia Therapeutics, Inc. - Common Stock

Starting at /week.